Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Cash: 2011-2025

Historic Change in Cash for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$80.7 million.

  • Abeona Therapeutics' Change in Cash fell 331.29% to -$80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 509.75%. This contributed to the annual value of $8.9 million for FY2024, which is 3370.31% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Change in Cash stood at -$80.7 million, which was down 154.64% from $147.6 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Change in Cash registered a high of $147.6 million during Q2 2025, and its lowest value of -$80.7 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Cash was $1.5 million (2023), whereas its average is $6.2 million.
  • Within the past 5 years, the most significant YoY rise in Abeona Therapeutics' Change in Cash was 991.78% (2024), while the steepest drop was 1,135.96% (2024).
  • Over the past 5 years, Abeona Therapeutics' Change in Cash (Quarterly) stood at -$5.9 million in 2021, then surged by 158.78% to $3.5 million in 2022, then skyrocketed by 180.17% to $9.8 million in 2023, then fell by 21.82% to $7.6 million in 2024, then plummeted by 331.29% to -$80.7 million in 2025.
  • Its last three reported values are -$80.7 million in Q3 2025, $147.6 million for Q2 2025, and -$7.4 million during Q1 2025.